Please find attached.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals reported FY26 revenue of INR 73.45 billion, up 10% YoY, with Q4 revenue of INR 18.48 billion growing 4% YoY. The company achieved PAT of INR 2.03 billion in Q4 (+29% YoY) and INR 6.75 billion for full year (+16% YoY). Pre-R&D EBITDA margin improved from 24% to 25%, indicating margin expansion. US formulation business grew 11% to INR 5.64 billion driven by 15 product launches, while India Branded Business grew 4% to INR 5.68 billion. R&D spending increased 39% to 11% of revenue due to peptide development and higher ANDA filings. Ex-US formulation de-grew 2% due to higher base effect.
The margin improvement from 24% to 25% demonstrates successful cost management and operating leverage, which should be positive for shareholders. The strong R&D investment signals commitment to pipeline development while maintaining profitability growth.